Journal: Heliyon

Article Title: KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway

doi: 10.1016/j.heliyon.2024.e29386

Figure Lengend Snippet: KIF15 was upregulated in chordoma and KIF15 knockdown cell model was established. (A) KIF15 protein expression in chordoma tumour tissues at different pathological stages, as determined by IHC staining. Primary antibody: KIF15, Secondary antibody: goat anti-rabbit IgG H&L (HRP). Magnification times: 400 × and 200 × . Scale: 50 μm. Arrows indicate positive KIF15 staining. (B, C) The KIF15 mRNA (B) and protein (C) expression in HEK-293T cells and chordoma cell lines were analyzed by qRT-PCT and Western blot. (D) The knockdown efficiencies of KIF15 in shKIF15 group were detected by Western blot. (E) The fluorescence expression in cells was observed after 72 h-infection. Magnification times: 200 × . Scale: 50 μm. (F) The expression of KIF15 protein in chordoma cell lines after infection was detected by Western blot. Results are presented as mean ± SD.

Article Snippet: After blocking, the membranes were probed with primary antibodies at room temperature for 2 h, which included KIF15 (1:2000, fine test, # FNab04551), AKT (1:2000, Proteintech, # 10176-2-AP), p -AKT (1:2000, Proteintech, # 66444-1-Ig), PI3K (1:2000, Proteintech, # 67071-1-Ig), p-PI3K (1:500, Bioss, bs-3332R) and GAPDH (1:3000, Bioworld, # AP0063).

Techniques: Knockdown, Expressing, Immunohistochemistry, Staining, Western Blot, Infection

Journal: Heliyon

Article Title: KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway

doi: 10.1016/j.heliyon.2024.e29386

Figure Lengend Snippet: KIF15 knockdown inhibited cell proliferation and migration. (A) The cell proliferation rate was evaluated in chordoma cell lines after infection by MTT assay. (B, C) The migration of chordoma cells was detected after infection by wound-healing assay (B) and transwell assay (C). Magnification times: 200 × . Scale: 50 μm. Results are presented as mean ± SD. ** P < 0.01, *** P < 0.001.

Article Snippet: After blocking, the membranes were probed with primary antibodies at room temperature for 2 h, which included KIF15 (1:2000, fine test, # FNab04551), AKT (1:2000, Proteintech, # 10176-2-AP), p -AKT (1:2000, Proteintech, # 66444-1-Ig), PI3K (1:2000, Proteintech, # 67071-1-Ig), p-PI3K (1:500, Bioss, bs-3332R) and GAPDH (1:3000, Bioworld, # AP0063).

Techniques: Knockdown, Migration, Infection, MTT Assay, Wound Healing Assay, Transwell Assay

Journal: Heliyon

Article Title: KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway

doi: 10.1016/j.heliyon.2024.e29386

Figure Lengend Snippet: The effects of KIF15 knockdown on cell apoptosis and cell cycle. (A) The effects of KIF15 knockdown on cell apoptosis were examined by flow cytometry. (B) The effects of KIF15 knockdown on cell cycle were determined by flow cytometry. (C, D) The effects of GW406108X (KIF15 Inhibitor) on cell proliferation (C) and apoptosis (D) in MUG-Chor1 and U–CH1 cells. Results are presented as mean ± SD. ** P < 0.01, *** P < 0.001.

Article Snippet: After blocking, the membranes were probed with primary antibodies at room temperature for 2 h, which included KIF15 (1:2000, fine test, # FNab04551), AKT (1:2000, Proteintech, # 10176-2-AP), p -AKT (1:2000, Proteintech, # 66444-1-Ig), PI3K (1:2000, Proteintech, # 67071-1-Ig), p-PI3K (1:500, Bioss, bs-3332R) and GAPDH (1:3000, Bioworld, # AP0063).

Techniques: Knockdown, Flow Cytometry

Journal: Heliyon

Article Title: KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway

doi: 10.1016/j.heliyon.2024.e29386

Figure Lengend Snippet: KIF15 knockdown suppressed chordoma growth in vivo . (A) A nude mice model of KIF15 knockdown was constructed. (B) The fluorescence intensity in mouse xenograft models was tested by injecting d -Luciferase before the mice were sacrificed. (C) Tumour volume was tested from feeding to sacrifice. (D) The photograph of tumours was taken after removing tumours. (E) The tumour's weight was weighed after sacrificing mice. (F) Ki67 expression in xenograft tumours was determined by IHC staining. Primary antibody: Ki67, Secondary antibody: goat anti-rabbit IgG H&L (HRP). Magnification times: 400 × and 200 × . Scale: 50 μm. Arrows indicate positive Ki67 staining. Results are presented as mean ± SD. * P < 0.05, ** P < 0.01.

Article Snippet: After blocking, the membranes were probed with primary antibodies at room temperature for 2 h, which included KIF15 (1:2000, fine test, # FNab04551), AKT (1:2000, Proteintech, # 10176-2-AP), p -AKT (1:2000, Proteintech, # 66444-1-Ig), PI3K (1:2000, Proteintech, # 67071-1-Ig), p-PI3K (1:500, Bioss, bs-3332R) and GAPDH (1:3000, Bioworld, # AP0063).

Techniques: Knockdown, In Vivo, Construct, Fluorescence, Luciferase, Expressing, Immunohistochemistry, Staining

Journal: Heliyon

Article Title: KIF15 promotes the development and progression of chordoma via activating PI3K-AKT signalling pathway

doi: 10.1016/j.heliyon.2024.e29386

Figure Lengend Snippet: KIF15 activates the PI3K-AKT pathway. (A) The signalling pathways related to KIF15 were obtained from KEGG analysis. (B) After being treated with 10 μM AKT activator, the total protein and phosphorylation levels of AKT and PI3K were evaluated in KIF15-silenced cells through Western blot. (C) After being treated with AKT activator, CCK8 assay showed the abilities to grow in KIF15-silenced MUG-Chor1 and U–CH1 cells. (D) Flow cytometry experiment detected cell apoptosis levels of KIF15-depleted MUG-Chor1 and U–CH1 cells following AKT activator addition. Results are presented as mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: After blocking, the membranes were probed with primary antibodies at room temperature for 2 h, which included KIF15 (1:2000, fine test, # FNab04551), AKT (1:2000, Proteintech, # 10176-2-AP), p -AKT (1:2000, Proteintech, # 66444-1-Ig), PI3K (1:2000, Proteintech, # 67071-1-Ig), p-PI3K (1:500, Bioss, bs-3332R) and GAPDH (1:3000, Bioworld, # AP0063).

Techniques: Phospho-proteomics, Western Blot, CCK-8 Assay, Flow Cytometry

Journal: JAMA

Article Title: Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure

doi: 10.1001/jama.2020.9524

Figure Lengend Snippet: Main Characteristics of Included Studies

Article Snippet: Delclaux et al, 38 2000 , Vital Signs Inc , 123 , CAP , 58 a , 144 , 33 , Face mask noninvasive ventilation (n = 62) , Standard oxygen (n = 61) , Death, intubation , ICU discharge, hospital discharge.

Techniques:

Journal: JAMA

Article Title: Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure

doi: 10.1001/jama.2020.9524

Figure Lengend Snippet: Network geometry shows nodes as interventions and each head-to-head direct comparison as lines connecting these nodes. There is no direct comparison between high-flow nasal oxygen and helmet noninvasive ventilation for any of the study outcomes. The size of the nodes is proportional to the number of participants in each node. The thickness of the connecting line is proportional to the number of randomized clinical trials in each comparison. Both network plots include 1 study (n = 47) that did not report any event of death or intubation and 1 three-group study (face mask noninvasive ventilation, high-flow nasal oxygen, and standard oxygen therapy). Therefore, the total number of comparisons is higher than the number of randomized clinical trials for each outcome. Patients may be included in multiple comparisons, and this is accounted within the bayesian model and does not mean participants are duplicated.

Article Snippet: Delclaux et al, 38 2000 , Vital Signs Inc , 123 , CAP , 58 a , 144 , 33 , Face mask noninvasive ventilation (n = 62) , Standard oxygen (n = 61) , Death, intubation , ICU discharge, hospital discharge.

Techniques: Comparison, Clinical Proteomics

Journal: JAMA

Article Title: Association of Noninvasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure

doi: 10.1001/jama.2020.9524

Figure Lengend Snippet: A, For the primary outcome, all-cause mortality, the longest follow-up was up to 90 days. B, For the secondary outcome, intubation, the longest follow-up was up to 30 days. All outcomes are reported as network risk ratios and absolute risk differences with 95% credible intervals (CrIs). The certainty for each network meta-analysis estimate was estimated based on the 4-step approach suggested by the GRADE Working Group. Initially, each direct and indirect comparison was rated independently using the GRADE approach (risk of bias, inconsistency, indirectness, imprecision), and these were used to rate the network estimate. In case of disagreement between the direct and indirect rating, the network estimate was assigned the higher rating. In the presence of incoherence, the network estimate was assigned the lower rating of the direct/indirect assessment. For estimating risk ratios for the comparison of helmet noninvasive ventilation vs high-flow nasal cannula, only indirect evidence was used because no direct pairwise comparisons were available. The estimated absolute risk of mortality and endotracheal intubation was 30% and 40%, respectively, in the standard oxygen group. Between-study heterogeneity was assessed by using the posterior distribution for τ, τ2, and the I2 statistic. For all-cause mortality, τ = 0.17 (95% CrI, 0.056-0.23), τ2 = 0.0284 (95% Crl, 0.00317-0.0508), and I2 = 12%. For endotracheal intubation, τ = 0.21 (95% CrI, 0.07-0.27), τ2 = 0.0437 (95% Crl, 0.00554-0.0743), and I2 = 15%.

Article Snippet: Delclaux et al, 38 2000 , Vital Signs Inc , 123 , CAP , 58 a , 144 , 33 , Face mask noninvasive ventilation (n = 62) , Standard oxygen (n = 61) , Death, intubation , ICU discharge, hospital discharge.

Techniques: Comparison